PROFILE |
 |
Shire-Biochem Pharma (formerly BioChem Pharma, now a subsidiary of the UK's Shire Pharmaceuticals) runs with the big boys. Through an alliance with UK pharmaceutical giant Glaxo Wellcome (now GlaxoSmithKline), the company developed 3TC (marketed outside of Canada as Epivir), the world's bestselling HIV treatment, which is used with Glaxo's Retrovir for the treatment of AIDS; and Zeffix, which is sold in over 30 countries for the treatment of chronic hepatitis B. Shire-BioChem also makes vaccines for the flu, meningitis, and pneumonia, and is developing treatments for bladder cancer.
COMPETITION |
 |
Abbott Laboratories (ABT)
Biogen, Inc. (BGEN)
Chiron Corporation (CHIR)
|
 |
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 216.80
1-Yr. Sales Growth: 13.7%
Employees: 500
Revenue per employee: $433,600.00
KEY PEOPLE |
 |
Joseph Rus
CEO
CONTACT INFO |
 |
275 Armand-Frappier Blvd.
Laval Quebec H7V 4A7, Canada
Phone: 1-450-978-7800
Fax: 1-450-978-7755
Online: Web Site
|